https://orcid.org/0000-0002-2876-8308
Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Robyn Kendall, Alan A Martin, Dhvani Shah, Soham Shukla, Chris Compton & Afisi S Ismaila. (2023) Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK. International Journal of Chronic Obstructive Pulmonary Disease 18, pages 1815-1825.
Read now
Read now
David MG Halpin, Robyn Kendall, Soham Shukla, Alan Martin, Dhvani Shah, Dawn Midwinter, Kai M Beeh, Janwillem WH Kocks, Paul W Jones, Chris Compton, Nancy A Risebrough & Afisi S Ismaila. (2022) Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 2745-2755.
Read now
Read now
Andrea Gabrio, Necdet B Gunsoy, Gianluca Baio, Alan Martin, Victoria F Paly, Nancy Risebrough, David MG Halpin, Dave Singh, Robert A Wise, MeiLan K Han, Fernando J Martinez, Gerard J Criner, Neil Martin, David A Lipson & Afisi S Ismaila. (2022) Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 1633-1642.
Read now
Read now
Rezwanul Hasan Rana, Khorshed Alam, Syed Afroz Keramat & Jeff Gow. (2022) Cost-effectiveness of single-inhaler triple therapy for patients with severe COPD: a systematic literature review. Expert Review of Respiratory Medicine 16:10, pages 1067-1084.
Read now
Read now
Mario Cazzola, Paola Rogliani, Luigino Calzetta, Josuel Ora & Maria Gabriella Matera. (2022) A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD. Expert Review of Clinical Pharmacology 15:3, pages 269-283.
Read now
Read now
Soham Shukla, Dhvani Shah, Alan Martin, Nancy A Risebrough, Robyn Kendall, Claus F Vogelmeier, Isabelle Boucot, Lee Tombs, Leif Bjermer, Paul W Jones, Edward Kerwin, Chris Compton, François Maltais, David A Lipson & Afisi S Ismaila. (2021) Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 3105-3118.
Read now
Read now
Leah B Sansbury, Robert P Wood, Glenn A Anley, Yein Nam & Afisi S Ismaila. (2021) Quantifying the Economic Impact of Delayed Multiple-Inhaler Triple Therapy Initiation in Patients with COPD: A Retrospective Cohort Study of Linked Electronic Medical Record and Hospital Administrative Data in England. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 2795-2808.
Read now
Read now
Tanja Fens, Guiling Zhou, Maarten J. Postma, Eugène P. van Puijenbroek & Job F.M. van Boven. (2021) Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?. Expert Opinion on Pharmacotherapy 22:7, pages 923-935.
Read now
Read now
Articles from other publishers (10)
Ching-Fu Weng, Chien-Chih Wu, Mei-Hsuan Wu & Fang-Ju Lin. (2023) Comparison of Clinical Outcomes Among Different Fixed-Dose Combinations of Long-Acting Muscarinic Antagonists and Long-Acting β2-Agonists in Patients With COPD. Chest 163:4, pages 799-814.
Crossref
Crossref
Safa Ahmadian, Don D Sin, Larry Lynd, Mark Harrison & Mohsen Sadatsafavi. (2022) Benefit–harm analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease. Thorax 77:11, pages 1079-1087.
Crossref
Crossref
Emanuela Resta, Giulia Scioscia, Donato Lacedonia, Carla Maria Irene Quarato, Francesco Panza, Onofrio Resta, Giorgia Lepore, Enrico Buonamico, Valentina Di Lecce, Giovanna Elisiana Carpagnano, Maria Pia Foschino Barbaro & Noemi Rossi. (2022) Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region. BMC Health Services Research 22:1.
Crossref
Crossref
Jia Liu, Xiaoning He & Jing Wu. (2022) Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model. Applied Health Economics and Health Policy 20:5, pages 743-755.
Crossref
Crossref
David Mannino, Michael Bogart, Benjamin Wu, Guillaume Germain, François Laliberté, Sean D. MacKnight, Young Jung, Marjorie Stiegler & Mei Sheng Duh. (2022) Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study. Respiratory Medicine 197, pages 106807.
Crossref
Crossref
A.L. Aguilar-Shea & C. Gallardo-Mayo. (2022) Revisión narrativa de la terapia inhalatoria en la EPOC. Medicina de Familia. SEMERGEN 48:3, pages 214-218.
Crossref
Crossref
Chih-Cheng Lai, Chao-Hsien Chen, Kuang-Hung Chen, Cheng-Yi Wang, Tsan-Ming Huang, Ya-Hui Wang & Hao-Chien Wang. (2022) The Impact of 52-Week Single Inhaler Device Triple Therapy versus Dual Therapy on the Mortality of COPD Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Life 12:2, pages 173.
Crossref
Crossref
Alan Martin, Dhvani Shah, Kerigo Ndirangu, Glenn A. Anley, Gabriel Okorogheye, Melanie Schroeder, Nancy Risebrough & Afisi S. Ismaila. (2022) Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial. ERJ Open Research 8:1, pages 00333-2021.
Crossref
Crossref
Maria Gabriella Matera, Paola Rogliani, Luigino Calzetta & Mario Cazzola. (2020) Triple Combination Inhalers in Chronic Obstructive Pulmonary Disease and Asthma. US Respiratory & Pulmonary Diseases 5:1, pages 18.
Crossref
Crossref
Safa Ahmadian, Donald Sin, Larry D. Lynd, Mark Harrison & Mohsen Sadatsafavi. (2021) A Benefit-Harm Analysis of Azithromycin for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. SSRN Electronic Journal.
Crossref
Crossref